secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001193125-25-007077
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir effects 1-for-23 reverse stock split effective Jan 15, 2025
-------------------------------------------------------------------

- Reverse split at 1-for-23 ratio, approved by board on Jan 9 after stockholder vote.
- Effective 4:05 pm ET Jan 15; trading on split-adjusted basis Jan 16 under ALVR.
- No fractional shares; cash in lieu based on Jan 15 closing price.
- Reverse split is part of preparations for proposed merger with Kalaris Therapeutics.
- New CUSIP number 019818202; par value and authorized shares unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/0001193125-25-007077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/d900097d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-007077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer